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SUMMARY
Background
Screening overweight and obese children for non-alcoholic fatty liver disease (NA-
FLD) is recommended by paediatric and endocrinology societies. However, gastro-
enterology societies have called for more data before making a formal
recommendation.
Aim
To determine whether the detection of suspected NAFLD in overweight and obese
children through screening in primary care and referral to paediatric gastroenterol-
ogy resulted in a correct diagnosis of NAFLD.
Methods
Information generated in the clinical evaluation of 347 children identified with sus-
pected NAFLD through screening in primary care and referral to paediatric gastro-
enterology was captured prospectively. Diagnostic outcomes were reported. The
diagnostic performance of two times the upper limit of normal (ULN) for alanine
aminotransferase (ALT) was assessed.
Results
Non-alcoholic fatty liver disease was diagnosed in 55% of children identified by
screening and referral. Liver disease other than NAFLD was present in 18% of those
referred. Autoimmune hepatitis was the most common alternative diagnosis. Chil-
dren with NAFLD had significantly (P < 0.05) higher screening ALT (98  95)
than children with liver disease other than NAFLD (86  74). Advanced fibrosis
was present in 11% of children. For the diagnosis of NAFLD, screening ALT two
times the clinical ULN had a sensitivity of 57% and a specificity of 71%.
Conclusions
Screening of overweight and obese children in primary care for NAFLD with refer-
ral to paediatric gastroenterology has the potential to identify clinically relevant liver
pathology. Consensus is needed on how to value the risk and rewards of screening
and referral, to identify children with liver disease in the most appropriate manner.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most
common cause of chronic liver disease in children.1 The
diagnosis of NAFLD requires that 5% or more hepato-
cytes have macrovesicular steatosis, and that other liver
diseases and/or clinical conditions, which may cause
steatosis, are excluded.2 Approximately 25% of children
with NAFLD have a progressive sub-phenotype known
as non-alcoholic steatohepatitis (NASH).3 Some children
with NASH will develop cirrhosis and end-stage liver
disease.4–6 Thus, NAFLD is not a singular diagnosis, but
a clinical–pathological diagnosis that encompasses a
broad spectrum of liver disease ranging from isolated
steatosis to steatohepatitis, fibrosis and cirrhosis.7
For the years 1993–2003, the prevalence of NAFLD in
children aged 2–19 years was estimated to be 9.6%.1
Studies have consistently shown that obesity is one of
the most important risk factors for paediatric NA-
FLD.1, 8–11 An overweight or obese child with elevated
alanine aminotransferase (ALT) is typically considered to
have suspected NAFLD.12 A recent report from the
National Health and Nutrition Examination Survey dem-
onstrated that the prevalence of suspected NAFLD in
children age 12–19 in the United States more than dou-
bled from 1988–1994 to 2007–2010.13
In 2005, a report from UC San Francisco and Stanford
University noted that general paediatricians were ‘un-
derscreening’ overweight children for NAFLD.14 Begin-
ning in 2007, major medical societies published guideline
statements regarding screening overweight and obese
children for NAFLD.15–17 The positions of these societies
are summarised in Table 1. Recommendations for
screening have been made by paediatricians, endocrinol-
ogists and paediatric gastroenterologists. The paediatric
guidelines state that overweight or obese children
≥10 years should be screened for NAFLD using serum
ALT and aspartate aminotransferase (AST).18 There is,
however, some controversy surrounding screening chil-
dren for NAFLD. Using published literature through
June 2011, the American Gastroenterology Association,
American Association for the Study of Liver Diseases
and the American College of Gastroenterology developed
a Practice Guideline on the diagnosis and management
of NAFLD, which was jointly published in Gastroenterol-
ogy,19 Hepatology20 and American Journal of Gastroenter-
ology21 in June 2012. The Practice Guideline states, ‘Due
to a paucity of evidence, a formal recommendation can-
not be made with regards to screening for NAFLD in
overweight and obese children despite a recent expert
committee recommendation for biannual screening for
liver disease with liver enzyme measurements in this
population’.
In the absence of uniform guidance, physicians must
make their own decision whether or not to screen over-
weight children for NAFLD. Many primary care provid-
ers are screening overweight and obese children for
NAFLD and many of these children identified as having
suspected NAFLD are referred to paediatric gastroenter-
ology for evaluation. The diagnostic outcomes for such
children with suspected NAFLD who were referred to
paediatric gastroenterology have not been reported.
Therefore, we sought to address critical gaps in the
knowledge base with the following study aims:
(i) To describe the population of children who were
identified with suspected NAFLD through screening in
primary care and referred to paediatric gastroenterology.
(ii) To determine whether the detection of suspected
NAFLD in overweight and obese children through screen-
ing in primary care and referral to paediatric gastro-
enterology resulted in a correct diagnosis of NAFLD.
Table 1 | Society guidelines regarding screening
overweight and obese children for NAFLD
Society
Recommend screening
children for NAFLD
Yes No Uncertain
Not
stated
American Academy
of Family Physicians
X
American Academy
of Pediatrics
X
American Association
for the Study of Liver
Disease
X
American College of
Gastroenterology
X
American
Gastroenterological
Association
X
Endocrine Society X
European Society for
Pediatric
Gastroenterology,
Hepatology, and Nutrition
X
National Association of
Pediatric Nurse
Practitioners
X
North American Society
for Pediatric
Gastroenterology,
Hepatology, and Nutrition
X
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(iii) To determine the frequency of NASH amongst
overweight and obese children who were identified with
suspected NAFLD through screening in primary care
and referred to paediatric gastroenterology.
(iv) To determine the frequency of advanced fibrosis
amongst overweight and obese children who were identi-
fied with suspected NAFLD through screening in pri-
mary care and referred to paediatric gastroenterology.
(v) To determine the diagnostic performance of ALT
two times the upper limit of normal (ULN) for the
above outcomes amongst overweight and obese children
who were identified with suspected NAFLD through
screening in primary care and referred to paediatric
gastroenterology.
METHODS
Study population
Screening for NAFLD and referral to paediatric gastroen-
terology were performed clinically in primary care prior
to participation in the study. Eligibility for this study
was designed to mirror the paediatric screening guide-
lines for NAFLD.18 Therefore, children had to be at least
10 years old and either overweight or obese. In the clini-
cal notes from the primary care office, there had to be
documentation of screening for NAFLD with ALT and
referral to paediatric gastroenterology for evaluation of
‘elevated ALT’ or ‘suspected NAFLD’ or ‘NAFLD’. There
was no study inclusion threshold set for ALT; rather, the
determination that the screening ALT was abnormal was
made by the primary care provider. The parent(s) of all
subjects provided written informed consent. Written
assent was obtained for all children. The protocol was
approved by the institutional review boards of the Uni-
versity of California, San Diego and Rady Children’s
Hospital San Diego.
Standard of care clinical evaluation of suspected
NAFLD
The clinical evaluation of the children was at the discre-
tion of the attending paediatric gastroenterologist and
not dictated by research protocol. Information generated
in the clinical evaluation of suspected NAFLD was cap-
tured prospectively. To provide clinical context for the
study, details of this diagnostic process are provided.
Paediatric gastroenterology clinic. All children under-
went a comprehensive history and physical as part of the
clinical consultation for suspected NAFLD. The history
included investigation of potential hepatotoxic medica-
tion intake as well as age-appropriate interviewing for
relevant lifestyle factors including unprotected sexual
activity, alcohol, tobacco and recreational drug use.
Height and weight were measured. Physical examination
also included assessment for signs of chronic liver dis-
ease.22–24 Initial laboratory studies performed in all chil-
dren at least 1 month after screening labs included
hepatic panel (ALT, AST, alkaline phosphatase, total
protein, albumin, total bilirubin, direct bilirubin) and
gamma glutamyl transferase (GGT) to assess the chro-
nicity and nature of aminotransferase elevation; complete
blood count to assess for anaemia and evidence of sple-
nic sequestration related to portal hypertension; and
coagulation studies to assess hepatic synthetic function.
If this confirmatory testing showed continued evidence
for liver disease, additional laboratory studies were per-
formed as ordered by the paediatric gastroenterologist
based on the clinical context. These labs included evalua-
tion of both hepatic aetiologies [hepatitis A IgM, hepati-
tis B surface antigen, hepatitis B surface antibody,
hepatitis C antibody, HIV ELISA, alpha-1 anti-trypsin
phenotype, anti-nuclear antibody (ANA), anti-smooth
muscle antibody (ASMA), anti-liver kidney microsomal
antibody, quantitative IgG, ceruloplasmin, 24-h urinary
copper measurement] and extra-hepatic aetiologies (tis-
sue transglutaminase IgA, quantitative IgA, serum amino
acids, urine organic acids, serum acylcarnitine, profile,
creatine kinase, erythrocyte sedimentation rate, C-reac-
tive protein, thyroid stimulating hormone and free thy-
roxine). In children who had no symptoms or signs of
liver disease by history or physical examination, and all
laboratory results were normal on confirmatory testing,
further evaluation was not pursued, given low likelihood
of liver disease. When there was evidence for chronic
liver disease based on history, physical and/or laboratory
testing, a percutaneous liver biopsy was offered for diag-
nosis.25
Liver biopsy. Children who underwent clinical liver
biopsy did so according to the standard clinical protocol
in use at our institution. Anaesthesia was provided by an
attending paediatric anaesthesiologist. Children under-
went a mask induction using a combination of gas
ventilation with oxygen, nitrous oxide and sevoflurane.
An intravenous line was placed and supplemental
propofol and fentanyl was given according to the anaes-
thesiologist’s discretion. Hemodynamic monitoring was
placed. Most patients were mask ventilated or had laryn-
geal mask airways placed. Ventilation was spontaneous.
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A time out was performed to confirm the correct patient
and procedure. Children were positioned supine, with
the right hand raised. Limited ultrasonography of the
liver was performed to identify the ideal biopsy path.
Liver biopsy was performed by an experienced paediatric
gastroenterologist using a 15-gauge Jamshidi needle. A
portion of tissue was placed in saline and brought afresh
to pathology and a portion was placed in formalin for
standard processing. After the procedure was completed,
patients were taken to the post-anaesthesia care unit
(PACU), monitored and observed for 4 h prior to
discharge.
Pathology. Pathology procedures were performed
according to standard clinical protocol within our insti-
tution. Formalin-fixed paraffin-embedded liver sections
were stained with haematoxylin and eosin, periodic acid
Schiff with and without diastase, Masson trichrome, reti-
culin and iron histochemical stains. Fresh frozen sections
were stained with oil-red-O. Slides were evaluated sys-
tematically (adequacy, overall architecture, portal tracts,
and parenchyma) by an experienced, board-certified,
paediatric pathologist. Additional stains were performed
and reviewed as needed based on the clinical context.
Fibrosis was staged using standard methods relevant to
the specific pathologic findings (e.g. Kleiner for NAFLD,
METAVIR for viral hepatitis, etc.).26, 27 The pathological
diagnosis was recorded.
Diagnosis. The final diagnosis was made by the paedi-
atric gastroenterologist incorporating all available
information from clinical interview, medical record,
physical examination, laboratory testing and review of
histopathology. A diagnosis of NAFLD was based on
exclusion of other causes of steatosis by clinical history,
laboratory studies and histology in addition to histo-
logic demonstration of ≥5% of hepatocytes containing
macrovesicular fat. Following the prevailing standard,
for those biopsies indicative of NAFLD, the diagnosis of
steatohepatitis was based on the pathologists’ interpreta-
tion of the global histological features including steato-
sis, lobular and portal inflammation and ballooning
degeneration of hepatocytes.26 The diagnoses of other
liver diseases were made based on relevant society
guidelines and standard gastroenterology, hepatology
and pathology reference textbooks.24, 28, 29 For example,
the diagnosis of autoimmune hepatitis was made follow-
ing the recommendations of the AASLD Practice
Guideline on the Diagnosis and Management of
Autoimmune Hepatitis.30
Data collection
Information generated in the clinical evaluation of sus-
pected NAFLD was captured prospectively. Age and sex
were recorded. Because race and ethnicity influence the
risk for NAFLD, each child’s race and ethnicity were
self-identified by the parent(s). Height and weight were
recorded. From the primary care provider’s office
records, the screening ALT and AST values were
recorded. In addition, from the paediatric gastroenterol-
ogy clinical record, we prospectively recorded the values
for laboratory assays performed for the evaluation of
liver disease. Adverse events were recorded as problems
in the operating room, patient complaints in the PACU,
return to the hospital, calls to gastroenterology and by
report at out-patient follow-up visit.
Data analysis
Calculated variables. Body mass index (BMI) was calcu-
lated as weight (kg) divided by height (m) squared. BMI
percentiles were determined from the Centers for Disease
Control and Prevention 2000 growth curves. BMI Z
scores (s.d.s from the national reference mean for a
given age and gender of children’s BMI values) also were
determined.
Definitions. Subjects were classified as overweight (BMI
85–94th percentiles) or obese (BMI ≥95th percentile).
The most common value used at children’s hospitals in
the United States for the ULN for ALT is 40 U/L.31
Therefore, two times the ULN was defined as 80 U/L.
This value was used to assess the diagnostic perfor-
mance of the paediatric guideline recommendation to
use two times the ULN for ALT as the threshold for
further evaluation. As a comparison, we also evaluated
recently proposed biology-based thresholds for the ULN
in children derived from the SAFETY study.31 These
are gender-specific with ULN of 25 U/L in boys and
22 U/L in girls. Therefore, two times the biology-based
ULN was defined as 50 U/L for boys and 44 U/L for
girls. Advanced fibrosis was defined as bridging fibrosis
or cirrhosis.
Statistics. Data were expressed as mean  standard
deviation (if not normally distributed, then geometric
means were reported) or frequency and percentage. Con-
tinuous variables were analysed with Student’s t-test; the
Mann–Whitney U test was used for nonparametric mea-
sures. The Pearson v2 test was used to test for differences
in proportions. All hypothesis tests were two-tailed.
Significance was defined a priori at a value of 0.05.
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Analyses were performed with Statistica 10 (StatSoft,
Inc., Tulsa, OK, USA).
We performed a post-hoc analysis of published indices
for NAFLD and advanced fibrosis using readily
available clinical data points.32 For the detection of
NAFLD, we tested the Fatty Liver Index (FLI).33 The
FLI was calculated as (e0.953*loge (triglycerides)
+ 0.139*BMI + 0.718*loge (GGT) + 0.053*waist circum-
ference15.745)/(1 + e0.953*loge (triglycerides) + 0.139*
BMI + 0.718*loge (GGT) + 0.053*waist circumfer-
ence15.745) 9 100. The index produces a score from 1
to 100. Scores of <30 are considered negative for NAFLD,
scores between 31 and 59 are considered indeterminate
and scores >60 are considered positive for NAFLD. For
the detection of advanced fibrosis, we tested the FIB-4
index.34, 35 This was calculated as (Age 9 AST)/(Plate-
lets 9 (sqr (ALT)). Values <1.3 are considered negative,
values between 1.3 and 2.67 are considered indeterminate
and values ≥2.67 are considered positive for advanced
fibrosis. Finally, we tested the Paediatric NAFLD Fibrosis
Index (PNFI).36 A linear predictor for PNFI was calcu-
lated as linear predictor (lp) = 6.539 9 loge [age
(years)] + 0.207 9 waist (cm) + 1.957 9 loge [triglyce-
rides (mg/dl)]  10.074. This linear predictor is trans-
formed into a PNFI score: (1/1 + e-lp) 9 10. PNFI scores
≥9 are considered positive for fibrosis. We tested for dif-
ferences in the PNFI score between those children with
and without advanced fibrosis.
RESULTS
Aim 1: demographics and clinical features
Children were screened and referred by 58 primary care
providers including 42 paediatricians, 9 family physicians
and 7 paediatric nurse practitioners. A study flow chart
is shown in Figure 1. We enrolled 347 children who met
eligibility criteria (were ≥10 years old, overweight or
obese, identified by primary care screening as having ele-
vated ALT and referred to paediatric gastroenterology
for suspected NAFLD). As shown in Table 2, the major-
ity of children were boys (223/347, 64%). The mean age
was 13.5 years. The majority of children were obese
(93%), with the remaining children being overweight
(7%). The mean screening ALT of children with sus-
pected NAFLD was 99 U/L. The screening ALT was
≥40 U/L in 90% (313/347) of children referred. The
screening ALT was higher than the gender-specific
biological ULN for all children referred for suspected
NAFLD.
Following clinical evaluation by a paediatric gastroen-
terologist, 21% (74/347) of children identified by screening
as having suspected NAFLD were determined not to have
liver disease based on the absence of symptoms or signs of
liver disease by history or physical examination, and nor-
mal laboratory results on confirmatory testing. The
remaining 273 children were offered clinical liver biopsy.
Liver biopsy was not performed in 6% of these children
due to either parental refusal (n = 4) or insurance denial
(n = 14). Notably, children whose parents refused liver
biopsy were significantly (P < 0.05) younger (11 year-
s-old) than the group overall (13 years-old). Moreover,
children who had liver biopsy denied by insurance were
significantly (P < 0.05) more likely to be Hispanic (92%)
than the group overall (70%). The remaining 255 children
successfully underwent liver biopsy. No child experienced
bleeding or required post-procedure hospitalisation. While
in the recovery room, 3% of patients reported symptoms
that were successfully resolved prior to discharge (five
complained of pain and two of nausea). After discharge to
home, one patient’s parent called about their child’s pain
which was successfully addressed over the telephone. All
children were seen for clinical follow-up and review of
biopsy results at a mean follow-up interval of 18 days
(range 4–97). At follow-up, an additional nine children
(3%) reported that they had experienced some degree of
minor discomfort after discharge post-liver biopsy. No
child was brought to urgent care nor required readmis-
sion.
Aim 2: diagnosis of NAFLD
The combination of histology, clinical and laboratory
features yielded a diagnosis of NAFLD in 55% of those
children identified by screening and referral (193/347)
and in 75% of those who underwent liver biopsy (193/
255). Liver histology was normal in three children (1%).
Liver disease other than NAFLD was present in 18% of
those referred (61/347) and 24% of those biopsied (61/
255). Notably, there were two children who had both
NAFLD and autoimmune hepatitis. As shown in Fig-
ure 2, boys had significantly (P < 0.01) higher ALT than
girls. Amongst subgroups, this was true both for children
without liver disease and for children with NAFLD.
However, ALT did not differ between boys and girls with
liver disease other than NAFLD.
For children with liver disease other than NAFLD,
autoimmune hepatitis was the most common diagnosis
(n = 11). Other forms of hepatitis included drug-induced
(n = 6), eosinophilic (n = 4), granulomatous (n = 1),
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idiopathic (n = 8), viral (hepatitis B, hepatitis C, each
n = 2), secondary to alcohol abuse (n = 2), associated
with herbal supplement (n = 1) and associated with
asymptomatic colitis (n = 1). Drug-induced hepatitis was
associated with medications including aripiprazole, cetiri-
zin, isotretinoin, minocycline and valproic acid. Microve-
sicular steatosis was present in 20 children and was
idiopathic in 10. Specific causes identified for microvesic-
ular steatosis included coeliac disease (n = 4), drug-in-
duced (n = 5) and muscle disease (n = 1). Additional
diagnoses included alpha-1-anti-trypsin deficiency
(n = 1), sclerosing cholangitis (n = 1) and congestive
hepatopathy (n = 1). As shown in Table 1, children with
liver disease other than NAFLD were significantly older,
more likely to be female and had lower ALT at both
screening and confirmation. Positive ANA was signifi-
cantly more frequent in children with liver disease other
than NAFLD (36%) than children with NAFLD (19%).
Aim 3: diagnosis of NASH
Non-alcoholic steatohepatitis was diagnosed in 105 chil-
dren who represent 30% of children who were identified
by screening and referred to paediatric gastroenterology,
41% of children who underwent liver biopsy, and 54% of
those children with NAFLD. Children with NASH had
significantly (P < 0.001) higher mean ALT at screening
(100  107 vs. 79  79 U/L) and at confirmation
(94  89 vs. 71  74 U/L) than children who did not
have NASH. However, there was no significant difference
in mean values of GGT, ceruloplasmin or frequency of
positive ANA or ASMA between children with and with-
out NASH.
Aim 4: diagnosis of advanced fibrosis
Advanced fibrosis was present in 11% (38/347) of all
children in the study population. The rate of advanced
fibrosis was greater in children with NAFLD (17%, 33/
193) than in children with liver disease other than
NAFLD (8%, 5/62). Advanced fibrosis was seen in auto-
immune hepatitis (n = 3), sclerosing cholangitis (n = 1)
and idiopathic hepatitis (n = 1). As a group, children
with advanced fibrosis did not significantly differ by age,
sex or severity of obesity. Children with advanced fibro-
sis did have significantly (P < 0.01) higher ALT
(120  140 U/L) and AST (79  87 U/L) than children
without advanced fibrosis (ALT 82  78 U/L, AST
57  45 U/L). Children with advanced fibrosis also had
significantly (P < 0.001) higher GGT (58  90) than
children without advanced fibrosis (35  41). Cerulo-
plasmin was also significantly (P < 0.05) higher in chil-
dren with advanced fibrosis (38  10) than children
without advanced fibrosis (33  8).
Aim 5: evaluation of ALT in the diagnostic process
Table 3 shows the study population separated into those
with screening ALT above and below two times the clini-
cal ULN. As expected children with screening ALT ≥80
had significantly higher ALT and AST than children
with screening ALT <80, but were otherwise not signifi-
cantly different with regard to age, sex, race, ethnicity,
height, weight or BMI. For children with screening ALT
≥80, NAFLD was diagnosed in 71% and liver disease
other than NAFLD was present in 14%. For children
with screening ALT that was elevated but <80, NAFLD
was diagnosed in 43% and liver disease other than
NAFLD in 22%. NASH was significantly (P < 0.01)
more common in children with screening ALT ≥80
(41%, 64/155) than in children with screening ALT <80
(21%, 41/192). Similarly, advanced fibrosis was
Screened by Primary Care and Referred to GI for Suspected Fatty Liver
N = 374
N = 347
N = 27
Exclude Age < 10 years
Age ≥ 10, overweight or obese
Evidence of
Chronic Liver
Disease
YES
N = 273
YES
N = 255
N = 193
N = 61
N = 3
Normal
NO
N = 74
NO
N = 18
Liver Biopsy
NAFLD Other Liver 
Disease
Figure 1 | Flow chart shows study the application of
inclusion and exclusion criteria along with progression
to final diagnosis. In the terminal nodes for diagnosis,
the cumulative number is greater than the number
biopsied because two children had dual diagnosis.
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significantly (P < 0.01) more common in children with
screening ALT ≥80 (19%, 29/155) than in children with
screening ALT <80 (6%, 9/192). For the diagnosis of
NAFLD in overweight and obese children ≥age 10,
screening ALT of ≥80 had a sensitivity of 57% and a
specificity of 71%. For the diagnosis of NASH, screening
ALT ≥80 had a sensitivity of 61% and a specificity of
62%. For advanced fibrosis, screening ALT ≥80 had a
sensitivity of 76% and a specificity of 59%.
As a comparison, we also analysed the diagnostic
accuracy of using two times the gender-specific, biol-
ogy-based, ALT thresholds. For the diagnosis of NAFLD
in overweight and obese children ≥age 10, ALT ≥50 for
boys and ≥44 for girls had a sensitivity of 88% and a
specificity of 26%. For the diagnosis of NASH, two times
the gender-specific biology-based thresholds had a sensi-
tivity of 90% and a specificity of 22%. For advanced
fibrosis, screening ALT ≥50 for boys and ≥44 for girls
had a sensitivity of 92% and a specificity of 19%.
Predictive indices
There were 270 children with FLI <30, of whom
163 (60%) had NAFLD. There were 75 children with
Table 2 | Characteristics of study population by diagnosis
Variables
Children identified by
screening, N = 347
Children with liver diagnosis
NAFLD, N = 193
Other liver disease,
N = 61
Age, mean (s.d.)** 13.5 (2.2) 13.6 (2.2) 14.5 (2.4)
Sex, N (%)**
Boys 223 (64) 140 (72) 29 (48)
Girls 124 (36) 53 (28) 32 (52)
Race and ethnicity, N (%)
Asian, non-Hispanic 16 (5) 8 (4) 6 (10)
Hispanic 252 (72) 147 (76) 38 (62)
White, non-Hispanic 45 (13) 21 (10) 12 (20)
Other, non-Hispanic 34 (10) 17 (8) 5 (8)
Weight, mean (s.d.) (kg) 80.1 (20.7) 81.5 (22.6) 80.8 (17.3)
Height, mean (s.d.) (cm) 157 (15.6) 157(15.0) 159 (12.6)
Body mass index (kg/m2)
Mean (s.d.) 31.5 (6.0) 31.5 (4.8) 31.4 (4.4)
Percentile, mean (s.d.) 98.1 (1.6) 98.4 (1.5) 97.4 (1.9)
Z-score, mean (s.d.) 2.2 (0.36) 2.2 (0.33) 2.0 (0.34)
ALT, mean (s.d.) (U/L)
Screening* 99 (89) 98 (95) 86 (74)
Confirmation** 80 (68) 89 (75) 75 (57)
AST, mean (s.d.) (U/L)
Screening 67 (50) 63 (55) 68 (57)
Confirmation 57 (39) 60 (43) 56 (30)
Statistical tests are for NAFLD vs. other liver disease.
* P < 0.05, **P < 0.001.
450
350
250
150
50
0
400
300
200
100
AL
T 
(U
/L)
Normal NAFLD Other
Figure 2 | Box and whiskers plot for screening ALT
separated by final diagnosis: no liver disease, NAFLD,
or liver disease other than NAFLD. Within each
diagnostic category, data are shown separately for boys
(○) and girls (□).The horizontal lines inside the boxes
represent the median, the box edges show the lower
and upper quartiles and the whiskers show the
minimum and maximum values. The Y axis was
truncated at 450 U/L. Only the group of boys with
NAFLD included outliers with screening ALT above
450 U/L.
Aliment Pharmacol Ther 2013; 38: 1267-1277 1273
ª 2013 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Evaluation of suspected NAFLD in children
indeterminate values (30–59) of whom 29 (39%) had
NAFLD. There were only two children who had a score
>60; one with NAFLD and one without NAFLD. Because
FLI only detected 1 of 193 children with NAFLD, further
diagnostic analysis was not performed. The mean FIB-4
score among children with advanced fibrosis was 0.34.
None of the 38 children with advanced fibrosis had a
positive FIB-4 score. For PNFI, there was no significant
(P = 0.92) difference between children with advanced
fibrosis (mean = 6) and children without advanced fibro-
sis (mean = 6).
DISCUSSION
We studied a large clinical sample of overweight and
obese children who were identified as having suspected
NAFLD by screening in primary care following paediat-
ric guidelines and referred to paediatric gastroenterology.
Children were evaluated by a paediatric gastroenterolo-
gist and those with evidence of chronic liver disease
underwent liver biopsy, which was well-tolerated. NA-
FLD was the most common diagnosis established. How-
ever, many children with suspected NAFLD were shown
to have liver disease other than NAFLD. Amongst chil-
dren with NAFLD, approximately half had steatohepati-
tis. Furthermore, many overweight and obese children
were determined to have previously unrecognised
advanced fibrosis.
Society recommendations to screen overweight and
obese children for NAFLD were based in part on the
asymptomatic nature of chronic liver disease that evades
diagnosis without a screening effort. The paediatric
guidelines as applied by primary care providers identified
many children with liver disease, most commonly
NAFLD. In addition, the current data demonstrated that
not all overweight and obese children with a positive
screening ALT will have liver disease. Thus, one major
challenge is the interpretation of ALT values. As shown
in the SAFETY study, there is wide institution-to-institu-
tion variability in the definition of the normal range for
ALT and controversy over whether or not to use multi-
pliers of the ULN.31 This creates confusion for paediatri-
cians, gastroenterologists and endocrinologists as well as
for the children themselves and their families. The cur-
rent data show the strengths and limitations of various
thresholds for ALT in children. The paediatric guidelines
suggest using two times the ULN as the criterion for
referral to paediatric gastroenterology. However, our data
suggest that primary care providers vary greatly in their
choice of threshold used for referral. Although the use of
two times the ULN would improve the specificity for
NAFLD, many children with NAFLD would be missed
including some with NASH and advanced fibrosis. In
addition, contrary to conventional wisdom, children with
liver disease other than NAFLD had lower ALT than
children with NAFLD. Thus, national standardisation of
ALT thresholds is needed, but no single ALT threshold
will be sufficient to be considered diagnostic.
Once the possibility of liver disease has been detected
by screening, it is important to make an accurate diagno-
sis. One important lesson from this study is that physi-
cians should not tell children that they have fatty liver
based solely on the finding of elevated ALT in the con-
text of obesity. Determining whether a child has NAFLD
or another form of liver disease has important therapeu-
tic implications, as many of the possible aetiologies have
specific therapies. Although it is true that some diseases,
such as hepatitis C, can be detected by serologic testing,
many other diseases, such as autoimmune hepatitis,
require liver biopsy to distinguish from NAFLD. In fact,
the screening test for autoimmune hepatitis, auto-anti-
bodies, has been reported to be positive in approximately
20% of patients with NAFLD.37 Indeed, in this study, a
Table 3 | Comparison of children with ALT above or
below 2 times upper limit of normal
Variables
Screening
ALT <80,
(N = 192)
Screening
ALT ≥80,
(N = 155)
Age, mean (s.d.) 13.5 (2.2) 13.6 (2.2)
Sex, N (%)
Boys 111 (58) 112 (72)
Girls 81 (42) 43 (28)
Race and ethnicity, N (%)
Asian, non-Hispanic 9 (4) 7 (4)
Hispanic 133 (69) 119 (76)
White, non-Hispanic 31 (16) 14 (9)
Other, non-Hispanic 19 (10) 15 (10)
Weight, mean (s.d.), (kg) * 77.8 (19.9) 83 (21.4)
Height, mean (s.d.) (cm) 157 (12.2) 158 (19.1)
Body mass index (kg/m2)
Mean (s.d.) 31.3 (6.9) 31.8 (4.5)
Z-score, mean (s.d.) 2.1 (0.3) 2.2 (0.3)
ALT, mean (s.d.) (U/L)
Screening** 54 (14) 156 (95)
Confirmation 59 (43) 107 (83)
AST, mean (s.d.) (U/L)
Screening 46 (20) 93 (63)
Confirmation* 45 (22) 71 (49)
Diagnosis
NAFLD, N (%) 83 (43) 110 (71)
Other liver disease, N (%) 42 (22) 21 (14)
* P < 0.05, **P < 0.001.
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positive ANA did not sufficiently distinguish between
those with NAFLD and those with autoimmune hepati-
tis. Because there are no alternative tests with satisfactory
diagnostic accuracy, liver biopsy remains the clinical
standard to determine the aetiology and stage of liver
disease. Liver biopsy is not without risk; however, the
current data show that when performed by experienced
personnel, it can be performed with minimal adverse
events.
The rationale for detecting NAFLD, and especially
NASH, is based in part on the risk for progression to
cirrhosis. In a national multi-centre study, advanced
fibrosis was reported at the time of diagnostic liver
biopsy in nearly one of seven children with NAFLD.38
Our study had similar findings, with 17% of children
with NAFLD having advanced fibrosis. The detection of
advanced fibrosis is important because these are the chil-
dren who in the short-term are at risk for portal hyper-
tension and its consequences, and in the long-term may
require liver transplant and/or develop hepatocellular
carcinoma.39 Beyond the hepatic consequences, obese
children with NAFLD are phenotypically distinct from
obese children without NAFLD. NAFLD is an indepen-
dent risk factor for diabetes and cardiovascular disease.40
In addition, children with NAFLD also have substantially
lower bone mineralisation than age- and adipos-
ity-matched peers.41 Thus, the early identification of
NAFLD has the potential to be clinically important.
The current study is notable for its large sample size
of overweight and obese children identified by screening
in primary care as having suspected NAFLD based on
prevailing national clinical guidelines and referred to
paediatric gastroenterology. In addition, data were avail-
able for detailed diagnostic outcomes based on history,
physical examination, laboratory evaluation, liver biopsy
and histology. These data represent children identified
by screening and not those tested based on symptoms,
thus may not reflect all overweight or obese children
with elevated liver chemistry. Moreover, given the influ-
ence of race and ethnicity, there are likely to be differ-
ences in findings depending upon the demographics of
the community being considered.
CONCLUSION
In conclusion, screening of overweight and obese chil-
dren in primary care for NAFLD with referral to paedi-
atric gastroenterology has the potential to identify
clinically relevant liver pathology. NAFLD was the most
common explanation for elevated ALT in children
detected by screening, but almost as common was either
the absence of liver disease or an alternative form of
chronic liver disease. The magnitude of ALT elevation
was associated with worse disease in group aggregate,
but was not an effective discriminate tool on the individ-
ual patient level. Importantly, the screening and referral
process followed by liver biopsy was able to identify
many obese children with advanced fibrosis that would
have otherwise remained undiagnosed. Proper treatment
of these children rests upon an accurate and definitive
diagnosis. Important next steps will include the assess-
ment of the cost and benefits of screening. These can be
evaluated at multiple different decision points including
initial screening for liver disease, referral for further eval-
uation of liver disease and the decision to perform liver
biopsy for definitive diagnosis and disease staging. The
current data can be used for efforts to develop a consen-
sus on how to value these risk and rewards. In turn, with
larger observational data, clinical practice guidelines can
be refined to best identify overweight children with liver
disease in the most appropriate manner.
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